Eli Lilly And Co (N:LLY)

Apr 22, 2024 04:00 am ET
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.
Apr 17, 2024 06:15 am ET
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials
Apr 16, 2024 10:00 am ET
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Feb 20, 2024 09:00 am ET
Lilly to Participate in Cowen's 44th Annual Health Care Conference
INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time.
Feb 15, 2024 08:45 am ET
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a substantial rate through the next decade. Fibromyalgia is a chronic condition whose symptoms severely impair...
Feb 12, 2024 08:31 am ET
Thinking about trading options or stock in Amazon, Eli Lilly, Altimmune, Novavax, or Snap?
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, LLY, ALT, NVAX, and SNAP.
Feb 09, 2024 08:30 am ET
Philip Johnson to Retire as Lilly Treasurer
INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.
Feb 08, 2024 08:31 am ET
Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP?
NEW YORK, Feb. 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FHTX, OSCR, LLY, PANW, and CNEY.
Feb 06, 2024 05:45 am ET
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoh
Jan 30, 2024 08:31 am ET
Thinking about trading options or stock in General Motors, Meta Platforms, Archer-Daniels-Midland, Eli Lilly, or Celestica?
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GM, META, ADM, LLY, and CLS.
Jan 26, 2024 08:31 am ET
Thinking about trading options or stock in Tesla, Amazon, Microsoft, Eli Lilly, or Halliburton?
NEW YORK, Jan. 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, AMZN, MSFT, LLY, and HAL.
Jan 25, 2024 07:00 am ET
Johna Norton to Retire as Lilly Executive Vice President of Global Quality
INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.
Jan 23, 2024 11:00 am ET
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss
Jan 23, 2024 09:00 am ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.
Jan 10, 2024 07:30 pm ET
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, and Shanghai Henlius Biotech, Inc. (2696.HK), today announced a...
Jan 10, 2024 08:31 am ET
Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon?
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TGTX, MSFT, LLY, CVX, and ALC.
Jan 04, 2024 08:31 am ET
Thinking about buying stock in Omega Therapeutics, Eli Lilly And Co, Cisco Systems, Applied Therapeutics, or Brooge Energy?
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OMGA, LLY, CSCO, APLT, and BROG.
Jan 04, 2024 06:30 am ET
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
Jan 02, 2024 09:00 am ET
Lilly to Participate in J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time.
Dec 27, 2023 08:31 am ET
Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences?
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS.
Dec 27, 2023 07:31 am ET
Lilly Completes Acquisition of POINT Biopharma
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
Dec 18, 2023 05:45 am ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
INDIANAPOLIS, Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
Dec 12, 2023 08:31 am ET
Thinking about trading options or stock in Meta Platforms, Eli Lilly, Micron Technology, Seagen Inc, or Cigna?
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for META, LLY, MU, SGEN, and CI.
Dec 11, 2023 06:30 pm ET
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle ce
Dec 11, 2023 09:54 am ET
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo
Dec 08, 2023 10:25 am ET
Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
INDIANAPOLIS, Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock.
Dec 05, 2023 07:15 am ET
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Sympo
Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women with visceral disease, however OS outcomes were not statistically significant
Dec 05, 2023 06:38 am ET
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
Express Scripts to add Zepbound to National Preferred Formulary
Dec 04, 2023 05:45 am ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
INDIANAPOLIS, Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
Dec 01, 2023 04:22 pm ET
Nov 30, 2023 08:31 am ET
Thinking about trading options or stock in Eli Lilly And Co, Apple, Uber Technologies, Pure Storage, or Salesforce?
NEW YORK, Nov. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, AAPL, UBER, PSTG, and CRM.
Nov 28, 2023 07:00 am ET
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of promising early-stage companies in the growing San Diego life science ecosystem
Nov 28, 2023 07:00 am ET
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies 
Nov 17, 2023 07:00 am ET
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany
Company also commits to investing up to $100 million in German early-stage life sciences ecosystem
Nov 17, 2023 05:45 am ET
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
INDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
Nov 14, 2023 03:33 pm ET
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining
Nov 14, 2023 09:00 am ET
Lilly to Participate in Evercore ISI HealthCONx Conference
INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:50 p.m., Eastern time.
Nov 13, 2023 08:31 am ET
Thinking about trading options or stock in Monday.Com, Boeing, Eli Lilly, Xpeng, or Genmab?
NEW YORK, Nov. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNDY, BA, LLY, XPEV, and GMAB.
Nov 13, 2023 07:30 am ET
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended...
Nov 09, 2023 08:31 am ET
Thinking about trading options or stock in Salesforce, Applovin, BILL Holdings, Eli Lilly And Co, or Ebix?
NEW YORK, Nov. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRM, APP, BILL, LLY, and EBIX.
Nov 08, 2023 03:56 pm ET
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
Nov 08, 2023 08:31 am ET
Thinking about buying stock in Cardio Diagnostics, Eli Lilly, Crowdstrike, NXU Inc., or Gan Ltd?
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDIO, LLY, CRWD, NXU, and GAN.
Nov 02, 2023 09:00 am ET
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
Nov 02, 2023 06:30 am ET
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.Pipeline progress included FDA approvals of Omvoh for the treatment of adults with moderately to severely active ulcerative colitis and an expanded indication for Jardiance in adults with chronic kidney disease, and positive results in the mirikizumab Phase 3 VIVID-1 study, which evaluated safety and efficacy fo
Nov 01, 2023 08:00 am ET
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature and the benefits of complete testingClinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) testsRIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 1, 2023 /PRNewswire/ -- More than 35 million adults in the U.S. have chronic kidney disease (CK
Nov 01, 2023 06:55 am ET
Lilly Declares Fourth-Quarter 2023 Dividend
INDIANAPOLIS, Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock.
Oct 26, 2023 06:24 pm ET
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials
Oct 26, 2023 10:00 am ET
Lilly to Participate in UBS Biopharma Conference 2023
INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
Oct 21, 2023 10:31 am ET
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Pre
- In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Oct 20, 2023 10:00 am ET
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Oct 20, 2023 08:00 am ET
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years
Oct 17, 2023 09:31 am ET
Thinking about trading options or stock in Tesla, Amazon.com, Camber Energy, Eli Lilly And Co, or Wyndham Hotels & Resorts?
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, AMZN, CEI, LLY, and WH.
Oct 15, 2023 06:00 pm ET
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek® 2023
Oct 13, 2023 09:00 am ET
Oct 12, 2023 06:45 am ET
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks
Oct 06, 2023 07:45 am ET
Lilly Announces Details of Presentations at ESMO Congress 2023
INDIANAPOLIS, Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid. 
Oct 04, 2023 12:05 pm ET
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston. These programs are among the next slate of new oncology agents planned to enter clinical trials for Loxo@Lilly in 2024.
Oct 04, 2023 06:45 am ET
Lilly Announces Leadership Transitions
INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.
Oct 03, 2023 11:37 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 03, 2023 06:45 am ET
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue.
Oct 02, 2023 06:45 am ET
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
In the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab
Sep 22, 2023 08:33 am ET
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD)Jardiance® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trialEMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a statistically significant reduction in the risk of first and recurrent hospitalization in adults with CKDRIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administrati
Sep 19, 2023 09:31 am ET
Thinking about trading options or stock in Palantir Technologies, Broadcom, Eli Lilly And Co, General Electric, or Taiwan Semiconductor?
NEW YORK, Sept. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, AVGO, LLY, GE, and TSM.
Sep 13, 2023 09:31 am ET
Thinking about trading options or stock in Adobe, Macy's, Rocket Pharmaceuticals, Eli Lilly And Co, or Broadcom?
NEW YORK, Sept. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADBE, M, RCKT, LLY, and AVGO.
Jul 27, 2023 06:48 am ET
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks
Jul 25, 2023 10:00 am ET
Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement
INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Jul 25, 2023 06:55 am ET
Lilly Announces Extension of Tender Offer to Acquire DICE
INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding.
Jul 17, 2023 10:15 am ET
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year
Jul 14, 2023 08:05 am ET
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
Medicxi co-led Company's US$70 million Series A less than 2 years agoThird Medicxi portfolio exit to US biopharma in last 12 monthsLONDON, GENEVA and JERSEY, British Isles, July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases, has entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, which is subjec
Jul 14, 2023 08:00 am ET
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
Jul 11, 2023 10:00 am ET
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
INDIANAPOLIS, July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will begin at 1:30 p.m. Eastern time, and remarks will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer's disease.
Jul 06, 2023 07:45 am ET
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
INDIANAPOLIS, July 6, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor.
Jun 29, 2023 06:45 am ET
Lilly to Acquire Sigilon Therapeutics
INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.
Jun 26, 2023 11:06 am ET
Lilly Declares Third-Quarter 2023 Dividend
INDIANAPOLIS, June 26, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock.
Jun 23, 2023 09:50 pm ET
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks
In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes
Jun 21, 2023 01:15 pm ET
US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
-  Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population-  More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S.
Jun 20, 2023 01:37 pm ET
Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions
Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes
Jun 20, 2023 08:00 am ET
Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"
Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community
Jun 20, 2023 06:45 am ET
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.
Jun 16, 2023 12:00 pm ET
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint
Jun 02, 2023 08:00 am ET
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting
New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose adjustments with benefit maintained at four-year follow-up; overall quality of life during the Verzenio treatment period shown to be similar to endocrine therapy alone
May 30, 2023 10:00 am ET
Lilly to Participate in Goldman Sachs Global Healthcare Conference
INDIANAPOLIS, May 30, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly executive vice president and chief financial officer, will participate in a fireside chat on June 12 at 4:20 p.m., Eastern time.
May 26, 2023 06:15 pm ET
Hagens Berman: Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit
Attorneys at Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello today announced a settlement with insulin-maker Eli Lilly worth more than $500 million, culminating a class-action lawsuit on behalf of insulin purchasers alleging systematic overpricing of insulin.
May 22, 2023 10:00 am ET
May 18, 2023 06:45 am ET
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA)
May 11, 2023 10:00 am ET
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
INDIANAPOLIS, May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses based on the BRUIN Phase 1/2 trial evaluating Jaypirca™ (pirtobrutinib) in patients with B-cell malignancies previously treated with a covalent Bruton's tyrosine kinase (BTK)
May 09, 2023 09:00 am ET
Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation
INDIANAPOLIS, May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments.
May 03, 2023 10:00 am ET
Lilly to Participate in Bank of America Securities 2023 Healthcare Conference
INDIANAPOLIS, May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat on Wednesday, May 10 at 1 p.m., Eastern time.
May 03, 2023 06:00 am ET
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB)
May 02, 2023 10:00 am ET
Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
INDIANAPOLIS, May 2, 2023 /PRNewswire/ -- To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced grants totaling $500,000 to four local nonprofits that offer education assistance to Deferred Action for Childhood Arrivals (DACA) recipients, also known as Dreamers.
May 01, 2023 01:02 pm ET
Lilly Declares Second-Quarter 2023 Dividend
INDIANAPOLIS, May 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding common stock.
May 01, 2023 06:45 am ET
Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
INDIANAPOLIS, May 1, 2023 /PRNewswire/ -- New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab's stable and long-lasting results at one year of treatment in patients with moderate-to-severe atopic dermatitis (AD), commonly called eczema. These r
Apr 28, 2023 09:59 am ET
Thinking about trading options or stock in Mondelez, Walmart, Eli Lilly, NVIDIA, or Apple?
NEW YORK, April 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDLZ, WMT, LLY, NVDA, and AAPL.
Apr 27, 2023 09:31 am ET
Thinking about trading options or stock in Amazon, Costco, Apple, Eli Lilly, or MicroStrategy?
NEW YORK, April 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, COST, AAPL, LLY, and MSTR.
Apr 27, 2023 06:45 am ET
Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum
Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth from Mounjaro, Trulicity, Verzenio and Jardiance.Pipeline progress included positive results in the tirzepatide Phase 3 SURMOUNT-2 study; FDA approval of an expanded indication for Verzenio; approval of mirikizumab in Japan; and regulatory submissions of tirzepatide for obesity in the EU and lebrikizumab for atopic dermatitis in Japan.New Products(i) contributed $573.6 million to revenue in Q1 2023, le
Apr 27, 2023 06:15 am ET
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg)
Apr 24, 2023 06:45 am ET
Lilly to Divest BAQSIMI to Amphastar
Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients
Apr 17, 2023 11:00 am ET
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities
In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs
Apr 13, 2023 04:30 pm ET
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab
INDIANAPOLIS, April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine.
Apr 13, 2023 10:00 am ET
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement
INDIANAPOLIS, April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Mar 14, 2023 04:30 pm ET
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
INDIANAPOLIS, March 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023. The presentations include the first clinical data from the Phase 1 studies of LY3537982 (KRAS G12C inhibitor) and LY3410738 (IDH inhibitor) and the Phase 2 study of Verzenio® (abemaciclib; CDK4/6 inhibitor) in metastatic treatment refractory castration-resistant prostate cancer. In addition, preclinical characterization data on Jaypirca's™ (p
Mar 08, 2023 04:00 pm ET
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease
Mar 08, 2023 08:00 am ET
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes
The application is based on phase III results from the DINAMO trial showing Jardiance® (empagliflozin) tablets significantly reduced A1c (a marker of average blood sugar) versus placebo in participants aged 10-17 living with type 2 diabetesIf approved, Jardiance would be the first SGLT2 inhibitor indicated for this vulnerable populationRIDGEFIELD, Conn. and INDIANAPOLIS, March 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) investigating a potential new indication to lower blood sugar along
Feb 13, 2023 05:00 am ET
Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh
Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh
Feb 07, 2023 09:00 am ET
Lilly to Participate in SVB Securities Global Biopharma Conference
INDIANAPOLIS, Feb. 7, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa, executive vice president and president, Lilly International, will participate in a virtual fireside chat at 12 p.m., Eastern time.
Feb 03, 2023 09:00 am ET
Lilly to Participate in Guggenheim Oncology Conference
INDIANAPOLIS, Feb. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden, executive vice president and CEO, Loxo@Lilly and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 10:10 a.m., Eastern time.
Feb 02, 2023 05:45 am ET
Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, partially offset by lower Alimta revenue. Excluding COVID-19 antibodies, total worldwide volume in Q4 2022 increased 13%. Pipeline advancements included FDA approval of Jaypirca for mantle cell lymphoma under the accelerated approval pathway and FDA and EMA acceptance of regulatory submissions for Jardiance for adults with chronic kidney disease. Additionally, the company initiated a rolling submission in the U.S
Jan 27, 2023 01:07 pm ET
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of
Jaypirca is the first BTK inhibitor of any kind specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor
Jan 26, 2023 09:00 am ET
Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity
$1.15M contribution from Lilly will fund the purchase and installation of 150 refrigeration units by Direct Relief in low- and middle-income countries around the world
Jan 24, 2023 05:30 am ET
Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines
Jan 20, 2023 08:00 am ET
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance® (empagliflozin) tablets significantly reduced the risk of kidney disease progression* or cardiovascular death in adults with CKD by 28% (absolute risk reduction [ARR]: 3.8%) compared with placebo, both on top of standard of care.
Jan 19, 2023 05:00 pm ET
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering
Jan 19, 2023 09:00 am ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement
INDIANAPOLIS, Jan. 19, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Jan 04, 2023 09:00 am ET
Lilly to Participate in the J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat at 6:45 p.m. Eastern time.
Dec 22, 2022 05:00 am ET
Lilly and ProQR to Expand RNA Editing Collaboration
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology
Dec 14, 2022 03:15 am ET
Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries
Dec 13, 2022 05:45 am ET
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for tirzepatide in obesity; and numerous other anticipated pipeline advancements.Continued pipeline progress in 2023 includes expected initiation of Phase 3 clinical trials for retatrutide (GGG tri-agonist) in obesity and orforglipron (oral GLP-1 NPA) in type 2 diabetes and obesity, and key Phase 3 readouts, which include donanemab for early Alzheimer's diseas
Dec 12, 2022 04:30 pm ET
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
Pirtobrutinib demonstrates activity across covalent BTK inhibitor pre-treated B-cell malignancies and multiple patient subgroups
Dec 12, 2022 02:26 pm ET
Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend
INDIANAPOLIS, Dec. 12, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock.
Dec 07, 2022 07:00 am ET
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged 10-17 living with type 2 diabetes compared to placeboSafety data in this vulnerable population was similar to that in adults with type 2 diabetes, confirming the well-established safety profile of JardianceINGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant re
Dec 06, 2022 02:00 pm ET
Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology
The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) rates of 6.4% and 5.9% at four years, respectively, in patients with HR+, HER2-, node-positive, high risk early breast cancer
Dec 01, 2022 07:41 am ET
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Nov 30, 2022 05:00 pm ET
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm® (aducanumab-avwa)-treated patients at 6 months
Nov 30, 2022 05:50 am ET
Lilly and Akouos Announce Expiration of Akouos Tender Offer
INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less an
Nov 29, 2022 09:00 am ET
Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement
INDIANAPOLIS, Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance.
Nov 21, 2022 08:00 am ET
Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium
INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually. These presentations include new results from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]), and LOXO-783 (an investigational mutant-selective allosteric PI3Kα H1047R inhibitor).
Nov 16, 2022 09:00 am ET
Lilly to Participate in Evercore ISI HealthCONx Conference
INDIANAPOLIS, Nov. 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 12:10 p.m., Eastern time.   
Nov 14, 2022 08:31 am ET
Thinking about trading options or stock in Alibaba, Biogen, Exxon Mobil, Eli Lilly, or Apple?
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, BIIB, XOM, LLY, and AAPL.
Nov 07, 2022 10:30 am ET
Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform
Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose loggingData shared through platform interface may help healthcare providers make data-driven decisions± about care for adults treated with select Lilly insulinsOffers compatibility with the Dexcom® Continuous Glucose Monitoring Systems, *,∞ the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs, as well as wearable devices from Fitbit®, Garmin®, Google Fit® and the Apple Health appINDIANAPOLIS, Nov. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will
Nov 04, 2022 10:30 am ET
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
-     EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice -     Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Nov 03, 2022 05:55 pm ET
AKOUOS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS
NEW ORLEANS, Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Akouos, Inc. (NasdaqGS: AKUS) to Eli Lilly and Company (NYSE: LLY).  Under the terms of the proposed transaction, shareholders of Akouos will receive only $12.50 in cash, plus one contingent value right (CVR) of up to $3.00 for each share of Akouos that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration under
Nov 03, 2022 09:00 am ET
Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting
INDIANAPOLIS, Nov. 3, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually. Pirtobrutinib is an investigational, highly selective, potent, reversible inhibitor of the Bruton's tyrosine kinase (BTK).
Nov 01, 2022 06:25 am ET
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%. Strong launch for Mounjaro led to $97.3 million in U.S. revenue in Q3 2022. The company also recognized $86.0 million in Mounjaro revenue related to a sales collaboration agreement for the right to sell and distribute Mounjaro in Japan.Pipeline advancements included the FDA granting Fast Track designation for tir
Oct 27, 2022 10:00 am ET
Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration
Scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college
Oct 21, 2022 04:17 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.
NEW YORK, Oct. 21, 2022 /PRNewswire/ --
Oct 19, 2022 10:00 am ET
Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement
INDIANAPOLIS, Oct. 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
Oct 18, 2022 06:50 am ET
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide
Oct 17, 2022 12:04 pm ET
Lilly Declares Fourth-Quarter 2022 Dividend
INDIANAPOLIS, Oct. 17, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock.
Oct 06, 2022 06:45 am ET
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
The Fast Track designation accelerates tirzepatide's path to U.S. FDA submission for the treatment of adults with obesity, or overweight with weight-related comorbidities
Sep 29, 2022 09:31 am ET
Thinking about trading options or stock in Freeport-McMoRan, Nasdaq, Rio Tinto, Eli Lilly, or Netflix?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FCX, NDAQ, RIO, LLY, and NFLX.
Sep 28, 2022 09:54 am ET
Thinking about trading options or stock in Eli Lilly, Royalty Pharma, Apple, Walt Disney, or Microsoft?
NEW YORK, Sept. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, RPRX, AAPL, DIS, and MSFT.
Sep 23, 2022 09:31 am ET
Thinking about trading options or stock in Apple, Eli Lilly, General Mills, Activision Blizzard, or Occidental Petroleum?
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, LLY, GIS, ATVI, and OXY.
Sep 22, 2022 11:25 am ET
Thinking about trading options or stock in Eli Lilly, Blackstone, Tesla, Adobe, or Walt Disney?
NEW YORK, Sept. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, BX, TSLA, ADBE, and DIS.
Sep 21, 2022 07:12 pm ET
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types
Sep 08, 2022 08:15 am ET
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severityResults suggest less frequent, every four week dosing of lebrikizumab provided similar improvements to every two week dosing Regulatory submissions for U.S. and EU planned for this yearINDIANAPOLIS, Sept. 8, 2022 /PRNewswire/ -- New detailed results from Eli Lilly and Company's (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and dur
Sep 07, 2022 06:05 pm ET
Lilly Announces Details of Presentations at ESMO Congress 2022
INDIANAPOLIS, Sept. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held September 9-13, 2022.
Aug 31, 2022 10:00 am ET
Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
INDIANAPOLIS, Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m., Eastern time.
Aug 25, 2022 10:00 am ET
Lilly to Participate in Citi's 17th Annual BioPharma Conference
INDIANAPOLIS, Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:30 p.m., Eastern time.                                                                   
Aug 22, 2022 09:31 am ET
Thinking about trading options or stock in Chesapeake Energy, Exxon Mobil, Apple, Eli Lilly, or Alibaba?
NEW YORK, Aug. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, XOM, AAPL, LLY, and BABA.
Aug 19, 2022 12:15 pm ET
Thinking about trading options or stock in General Motors, 3M, Eli Lilly, UnitedHealth, or General Electric?
NEW YORK, Aug. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GM, MMM, LLY, UNH, and GE.
Aug 17, 2022 12:31 pm ET
Thinking about trading options or stock in Lowe's, Progressive, Home Depot, Eli Lilly, or Costco?
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LOW, PGR, HD, LLY, and COST.
Aug 11, 2022 08:30 am ET
Aug 08, 2022 06:45 am ET
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz
Aug 04, 2022 09:52 am ET
Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
INDIANAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.
Aug 04, 2022 06:25 am ET
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than offset volume growth from key growth products. Total revenue grew 6% excluding revenue from Alimta, the sale of the company's rights to Cialis in China in Q2 2021, and COVID-19 antibodies.The company continued to advance its pipeline with the U.S. approval and launch of Mounjaro for type 2 diabetes, approval in the U.S., EU and Japan of Olumiant for alopecia areata, and FDA acceptance with Priority Review desig
Aug 02, 2022 11:15 am ET
Thinking about trading options or stock in Alibaba, Eli Lilly, NVIDIA, Intuitive Surgical, or Tesla?
NEW YORK, Aug. 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, LLY, NVDA, ISRG, and TSLA.
Jul 21, 2022 10:00 am ET
Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement
INDIANAPOLIS, July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
Jun 29, 2022 06:45 am ET
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
Bebtelovimab continues to maintain neutralization against all known variants of interest and concern
Jun 27, 2022 01:26 pm ET
Lilly Declares Third-Quarter 2022 Dividend
INDIANAPOLIS, June 27, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock.
Jun 27, 2022 09:31 am ET
Thinking about trading options or stock in SYSCO Corp, Nike, Eli Lilly, Gitlab, or Atlassian?
NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYY, NKE, LLY, GTLB, and TEAM.
Jun 23, 2022 09:31 am ET
Thinking about trading options or stock in Eli Lilly, Centene Corp, Snowflake, Apple, or Winnebago?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, CNC, SNOW, AAPL, and WGO.
Jun 13, 2022 09:50 pm ET
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.1 The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treat
Jun 07, 2022 11:00 am ET
Thinking about trading options or stock in Amazon, ConocoPhillips, Pinduoduo, Eli Lilly, or Take-Two Interactive?
NEW YORK, June 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, COP, PDD, LLY, and TTWO.
Jun 07, 2022 12:01 am ET
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed
Jun 06, 2022 07:00 pm ET
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®
Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study
Jun 05, 2022 04:30 pm ET
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence s
Jardiance showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitors in the subset of people with Medicare coverageData from these final analyses of EMPRISE complements findings from the landmark EMPA-REG OUTCOME® trialRIDGEFIELD, Conn. and INDIANAPOLIS, June 5, 2022 /PRNewswire/ -- Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance® (empagliflozin) was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of gluc
Jun 04, 2022 11:00 am ET
Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo
AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population
Jun 04, 2022 10:02 am ET
Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's® 82nd Scientific Sessions® and simultaneously published in NEJM
Jun 03, 2022 10:00 am ET
Lilly to Participate in Goldman Sachs Global Healthcare Conference
INDIANAPOLIS, June 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White, senior vice president and president, Lilly Neuroscience, and Mark Mintun, senior vice president, research and development – neuroscience and president, Avid Radiopharmaceuticals, will participate in a fireside chat at 1:40 p.m., Eastern time.
May 27, 2022 09:31 am ET
Thinking about trading options or stock in Dell Technologies, Boot Barn, Pinduoduo, Apple, or Eli Lilly?
NEW YORK, May 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DELL, BOOT, PDD, AAPL, and LLY.
May 26, 2022 05:00 pm ET
Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
INDIANAPOLIS, May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022. The data include new analyses from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a selective RET inhibitor), and imlunestrant (an investigational, oral selective estrogen receptor degrader [SERD]). 
May 25, 2022 01:15 pm ET
Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana
INDIANAPOLIS, May 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
May 24, 2022 03:01 am ET
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids
May 23, 2022 05:00 pm ET
Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
INDIANAPOLIS, May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast will begin at 11:30 a.m. Eastern time and remarks will focus on results from the tirzepatide SURMOUNT-1 clinical trial, as well as Lilly's once-weekly basal insulin and early-phase incretins.
May 20, 2022 08:11 am ET
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
INDIANAPOLIS, May 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).
May 16, 2022 02:00 pm ET
Lilly to Participate in UBS Global Healthcare Conference 2022
INDIANAPOLIS, May 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 24, 2022. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in a fireside chat at 8:30 a.m., Eastern time.
May 16, 2022 10:45 am ET
Thinking about trading options or stock in Coinbase Global, Chevron, Cloudflare, Shopify, or Eli Lilly?
NEW YORK, May 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COIN, CVX, NET, SHOP, and LLY.
May 13, 2022 05:54 pm ET
May 11, 2022 06:45 am ET
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support
May 06, 2022 02:00 pm ET
Mary Lynne Hedley Elected to Lilly Board of Directors
INDIANAPOLIS, May 6, 2022 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a member of Lilly's board, she will serve on both the Science & Technology Committee and the Ethics and Compliance Committee. 
May 03, 2022 02:00 pm ET
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
INDIANAPOLIS, May 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Tuesday, May 10 at 7:40 p.m., Eastern time.
May 02, 2022 02:26 pm ET
Lilly Declares Second-Quarter 2022 Dividend
INDIANAPOLIS, May 2, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock.
Apr 29, 2022 09:31 am ET
Thinking about trading options or stock in Apple, Pinduoduo, Alibaba, Baidu, or Eli Lilly?
NEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, PDD, BABA, BIDU, and LLY.
Apr 28, 2022 06:25 am ET
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%.Outside of revenue from COVID-19 antibodies, which grew $660 million, revenue was driven by key growth products - consisting of Trulicity, Verzenio, Jardiance, Taltz, Olumiant, Emgality, Retevmo, Cyramza and Tyvyt - which contributed 13 percentage points of revenue growth and represented 61% of core revenue in Q1 2022.The company advanced its pipeline with a positive Phase 3 readout for tirzepatide for obesity or overweight, an annou
Apr 28, 2022 06:15 am ET
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Apr 20, 2022 09:00 am ET
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Boehringer Ingelheim and Lilly launch Hear Your Heart™, an empowering health initiative to provide resources and education for women with heart failure, especially Black and Latina women, to help optimize their care.As of 2019, heart disease, which includes heart failure, was the number one cause of death in the U.S. Heart failure impacts more than six million people nationwide, approximately half of which are women.RIDGEFIELD, Conn. and INDIANAPOLIS, April 20, 2022 /PRNewswire/ -- Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes c
Apr 19, 2022 10:00 am ET
Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
INDIANAPOLIS, April 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
Apr 11, 2022 10:15 am ET
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, includingskin and itch, in pivotal combination trial that met all primary and key secondary endpoints
Apr 07, 2022 09:31 am ET
Thinking about trading options or stock in New Fortress Energy, Eli Lilly, Tesla, CMS Energy, or Pfizer?
NEW YORK, April 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NFE, LLY, TSLA, CMS, and PFE.
Apr 06, 2022 11:29 am ET
Thinking about trading options or stock in Twitter, Qualcomm, Mosaic, AbbVie, or Eli Lilly?
NEW YORK, April 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWTR, QCOM, MOS, ABBV, and LLY.
Apr 01, 2022 06:45 am ET
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
INDIANAPOLIS, April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (marketed as Retsevmo® outside of the U.S.) is a selective and potent RET kinase inhibitor that is approved in multiple countries including the United States for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive NSCLC, and the treatment of adult and pediatric patients 1
Mar 27, 2022 08:00 pm ET
Innovent and Lilly Expand Strategic Partnership in Oncology
SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that in light of both parties' shared commitment to continue bringing innovative medicines to benefit Chinese patients and to leverage the strengths of each party in a win-win manner, parties will now expand the str
Mar 26, 2022 11:20 am ET
Mar 26, 2022 09:20 am ET
Mar 24, 2022 06:45 am ET
Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
INDIANAPOLIS, March 24, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). Sintilimab is being developed by Innovent Biologics, Inc. (HKEX: 01801) and Lilly.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.